Septa Pharmaceuticals Inc. Acquires CeeNU® (Lomustine) from Bristol Myers Squibb, Canada

CeeNU®Positive

AI Analysis

Summary

Septa Pharmaceuticals acquired the marketed oncology drug CeeNU® (Lomustine) from Bristol Myers Squibb Canada, effective June 29, 2026, expanding its product portfolio in the Canadian healthcare market.

Outcome Details

Septa Pharmaceuticals acquired CeeNU® (Lomustine) from Bristol Myers Squibb Canada effective June 29, 2026

Importance:4/10

Sentiment:

0.50

M&Aproduct acquisitionCanadaoncology

Related Companies

$BMY

Read the original article

Published by PR Newswire Pharma on July 15, 2026 11:00 AM

Read Original